Dear CMT Community, Trial Participants, and Families,

We are thrilled to share an important milestone for the Charcot-Marie-Tooth (CMT) community. As of **October 6, 2025**, the **final participant has been enrolled** into NMD Pharma's Phase 2 SYNAPSE-CMT clinical trial.

We would like to sincerely acknowledge the global CMT community for your extraordinary interest, encouragement, and willingness to spread awareness about this study.
If you took part in the trial or reached out to a site with interest in participating, we extend our deepest gratitude. Your time, travel, and commitment represent a real and personal sacrifice - one made not only for yourselves or your families, but for the broader CMT community worldwide. The knowledge gained from your participation is invaluable, helping us better understand our investigational therapy, **NMD670**, and progress forward to realize its potential to improve life for people living with CMT.

In under a year, and thanks to your continued support, we successfully enrolled **81 participants with CMT types 1 and 2** (one more than our targeted enrollment) across study sites in the United States and Europe. The goal of the study is to evaluate the **safety and efficacy** of NMD670, an investigational, first-in-class therapy designed to **improve muscle function** by targeting the **chloride ion channel** (**ClC) type 1** found exclusively in skeletal muscle.
For those living with CMT, this approach aims to enhance muscle strength, reduce fatigue, and support greater balance and mobility.

What's Next

The final group of participants is now completing their in-clinic visits. In parallel, our team at NMD Pharma is working closely with investigators, data experts, and statisticians to ensure all study information is collected, verified, and analyzed to the highest scientific standards.

We anticipate being able to share an update with the entire CMT community on the **outcomes of the SYNAPSE-CMT trial in early 2026.**
If the results are positive, we will move forward—together—with the planning of the **next (and potentially final) phase of clinical studies.**
These next studies will be designed in collaboration with physicians, researchers, and most importantly, **people living with CMT** across diverse healthcare settings worldwide. We will also engage with regulators, including the **FDA and EMA**, to align on the path toward making this potential new therapy available as soon as possible to all who may benefit.

From everyone at NMD Pharma, **thank you for being part of this journey.** Your courage, generosity, and partnership inspire our work every day.

Together, we're turning hope into action.

Warm regards,
The NMD Pharma Team